A recent study places Fresenius among the top 500 companies in terms of career training programs in Germany. Criteria used for judgement were the quality of supervision, in-house training, company engagement, success rate and innovative teaching methods. The companies were rated by the business magazine Capital and the internet portal, ausbildung.de. Fresenius received a best possible five-star rating for its on-the-job training and dual-studies, a combination of theory and on-the-job training, programs. The company trains more than 4,000 apprentices and dual-studies interns.
Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, has acquired Clínica Medellín and entered the attractive private hospital market in Colombia. Clínica Medellín operates two centrally located hospitals in Medellín, a major city of 2.5 million people. The two facilities have a total of about 185 beds. The total investment for Clínica Medellín is more than €50 million. Following Quirónsalud's entry into Peru last year, this is another step in strengthening the company’s presence in Latin America’s growing and consolidating hospital markets. Fresenius Helios expects the transaction to close in Q1 2019, pending anti-trust and regulatory clearance.
Fresenius Kabi has opened a new state-of-the-art compounding center in Canada. It involves an investment of 11 million Canadian dollars (more than €7 million), and the new site expands the company’s presence in Mississauga, Ontario. Fresenius Kabi is responding to increasing demand for large batches of compounded medications for patients in Canadian hospitals, and the 35,000-square-foot (3,300-square-meter) compounding center has the capacity to expand. The new facility is expected to employ 70 people by 2022.
Fresenius Kabi has reached a milestone on the road to approval for another biosimilar. MSB11455, a biosimilar candidate for Neulasta® (pegfilgrastim), has met its primary endpoints in the two pivotal clinical studies. For more information please see the website of Fresenius Kabi.
The price increase for hospital services in Germany has been set at 2.65% for 2019. This is in line with the level of past years.
Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, is opening a new hospital in Cordoba today. The company now has six hospitals in Andalusia, Spain’s most southernly autonomous community. The six-floor, approximately 25,000-square-meter (269,000-square-foot) facility includes 100 large private patient rooms, a 24-hour emergency department, seven operating rooms and a surgical outpatient clinic. Quirónsalud has invested €50 million in the new hospital.
Fresenius Medical Care North America is making a $100,000 contribution to the American Nephrology Nurses Association (ANNA), a professional nursing organization with more than 8,500 members. In recognition of ANNA’s 50th anniversary year and Nephrology Nurses Week, the donation will fund an ongoing scholarship program, help increase awareness of the profession, and strengthen engagement with nurses dedicated to caring for patients with chronic kidney disease.
Fresenius Helios has opened a new emergency unit at Helios Hospital Leisnig, in the eastern German state of Saxony. It contains four modern examination rooms and a specially equipped reanimation room, which will enable the hospital to provide even better care for its emergency patients, who now number some 10,000 annually. Architecturally optimized for medical processes and procedures, the new emergency unit was built in only 12 months. It required an investment by Fresenius Helios of about €1 million.
Fresenius Helios will take responsibility for practical instruction as part of the first worldwide digitalized medical studies program. The new course of study meets European certification standards and will start in the winter semester 2018/2019 at the EDU College of Medicine, Malta. Theoretical components of a bachelor’s and follow-on master’s program will be available solely via an online platform. Students will be networked into learning communities taught by faculty. About one-third of the course is practical instruction that will take place in hospitals operated by Fresenius Helios in Germany. The program initially will be limited to 75 students. The long-term goal is up to 3,000 students.
Fresenius Kabi is expanding its production and warehouse capacity in Runcorn, England, to meet increasing demand in United Kingdom’s homecare market and from UK and Ireland hospitals. The expansion’s first stage will be a new distribution and operations center, scheduled to open in early 2019. A second services unit for producing aseptically compounded parenteral nutrition products will be completed by 2020. Fresenius Kabi will invest over €9 million in the expansion.
Fresenius Factsheet Q3/2018 (PDF, 469 KB)
Annual Report 2017 (IFRS) (PDF, 3.21 MB)
Fresenius "At a Glance" (PDF, 1.13 MB)
Book "100 Years of Fresenius" (PDF, 6.25 MB)
Fresenius Medical Care "Profile" (PDF, 351 KB)
Fresenius Medical Care Magazine "Creating added value" (PDF, 3.09 MB)
Social Media Guidelines (PDF, 1.97 MB)
Investor Relations General Presentation (PDF, 1.55 MB)